Gilead recorded a loss of $3.9 billion in Q4 because of a one-off charge linked to US tax reforms – however it has bigger problems because of the decline in its hepatitis C portfolio.<
Pharma often accuses the NHS of being behind the curve when it comes to adopting the latest CAR-T therapies – but England's health service is already doing the groundwork to get the la
